Clinical Efficacy and sAfety of Intravenous Infusion of Nicorandil During Primary Percutaneous Coronary Intervention

Impact of Intravenous Administration of Nicorandil as Adjuncts to Reperfusion Treatment for Acute ST Segment Elevation Myocardial Infarction: a Multi-center Randomized Controlled Trial

The investigators evaluate the efficacy and safety of intravenous administration of nicorandil as adjuncts to reperfusion treatment in acute ST-segment elevation acute myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention (PCI).

Inclusion Criteria:

• 18-80 years;
• acute ST-segment elevation myocardial infarction within 12 hours of symptom onset;

Exclusion Criteria:

• systolic blood pressure<100mmHg;
• cardiac shock;
• aortic dissection;
• history of myocardial infarction or percutaneous coronary intervention or coronary artery bypass grafting (<6 month);
• history of the treatment of nicorandil (<6 month);
• history of intravenous nitrates before percutaneous coronary intervention;
• contraindicated or intolerable to nicorandil;
• pregnant or lactation period;
• patients with an estimated survival time of less than 1 year.